Research ArticleArticle
Open Access
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States
Karina Raimundo, Amanda M. Farr, Gilwan Kim and George Duna
The Journal of Rheumatology December 2015, 42 (12) 2383-2391; DOI: https://doi.org/10.3899/jrheum.150479
Karina Raimundo
From Genentech Inc., South San Francisco, California; Truven Health Analytics, Bethesda, Maryland,
USA.
Amanda M. Farr
Gilwan Kim
REFERENCES
- 1.↵
- Langford CA
- 2.↵
- 3.↵
- 4.↵
- Flossman O,
- Berden A,
- de Groot K,
- Hagen C,
- Harper L,
- Heijl C,
- et al.
- 5.↵
- Mahr AD
- 6.↵
- Zeft AS,
- Weiss N
- 7.↵
- 8.↵
- Ntatsaki E,
- Carruthers D,
- Chakravarty K,
- D’Cruz D,
- Harper L,
- Jayne D,
- et al.
- 9.↵
- Tarzi RM,
- Pusey CD
- 10.↵
- 11.↵
- Stone JH,
- Merkel PA,
- Spiera R,
- Seo P,
- Langford CA,
- Hoffman GS,
- et al.
- 12.↵Rituximab package insert. South San Francisco, CA: Genentech Inc.; 2014.
- 13.↵
- Koldingsnes W,
- Nossent JC
- 14.↵
- 15.↵
- 16.↵
- 17.↵
- US Bureau of Labor
- 18.↵
- 19.↵
- 20.↵
- 21.↵
- Mittal SK,
- Ahern L,
- Flaster E,
- Maesaka JK,
- Fishbane S
- 22.↵
- 23.↵
- 24.↵
- Cotch MF,
- Hoffman GS
In this issue
The Journal of Rheumatology
Vol. 42, Issue 12
1 Dec 2015
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States
Karina Raimundo, Amanda M. Farr, Gilwan Kim, George Duna
The Journal of Rheumatology Dec 2015, 42 (12) 2383-2391; DOI: 10.3899/jrheum.150479